# reload+after+2024-01-20 19:47:15.571589
address1§42505 Tenth Street West
city§Lancaster
state§CA
zip§93534-7059
country§United States
phone§661 723 7723
website§https://www.simulations-plus.com
industry§Health Information Services
sector§Healthcare
longBusinessSummary§Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
fullTimeEmployees§192
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Walter S. Woltosz M.A.S., M.S.', 'age': 78, 'title': 'Co-Founder & Chairman', 'yearBorn': 1945, 'fiscalYear': 2023, 'totalPay': 80000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Mr. Shawn M. O'Connor", 'age': 63, 'title': 'Chief Executive Officer', 'yearBorn': 1960, 'fiscalYear': 2023, 'totalPay': 847564, 'exercisedValue': 0, 'unexercisedValue': 582400}, {'maxAge': 1, 'name': 'Mr. William  Frederick', 'age': 59, 'title': 'CFO & Secretary', 'yearBorn': 1964, 'fiscalYear': 2023, 'totalPay': 443121, 'exercisedValue': 1294, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John Anthony DiBella M.S.', 'age': 43, 'title': 'President of PBPK, Cheminformatics & Regulatory Strategies Solutions', 'yearBorn': 1980, 'fiscalYear': 2023, 'totalPay': 399803, 'exercisedValue': 2132131, 'unexercisedValue': 1468671}, {'maxAge': 1, 'name': 'Dr. Brett A. Howell Ph.D.', 'age': 40, 'title': 'President of Quantitative Systems Pharmacology Solutions', 'yearBorn': 1983, 'fiscalYear': 2023, 'totalPay': 321667, 'exercisedValue': 0, 'unexercisedValue': 235558}, {'maxAge': 1, 'name': 'Ms. Jill  Fiedler-Kelly M.S.', 'age': 54, 'title': 'President of Clinical Pharmacology & Pharmacometrics Services', 'yearBorn': 1969, 'fiscalYear': 2023, 'totalPay': 393770, 'exercisedValue': 17425, 'unexercisedValue': 895490}, {'maxAge': 1, 'name': 'Ms. Viera  Lukacova Ph.D.', 'title': 'Chief Science Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Bud  Nelson J.D., Ph.D.', 'title': 'VP of Corporate Counsel & Personal Data Protection Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Arlene  Padron', 'title': 'Corporate Director of Marketing', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lindsay  Luke', 'title': 'Executive Director of Human Resources', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§5
compensationRisk§6
shareHolderRightsRisk§1
overallRisk§2
governanceEpochDate§1704067200
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§2
dividendRate§0.24
dividendYield§0.006
exDividendDate§1706227200
payoutRatio§0.45279998
fiveYearAvgDividendYield§0.58
beta§0.679
priceToSalesTrailing12Months§12.858564
currency§USD
dateShortInterest§1702598400
forwardEps§0.8
pegRatio§4.14
exchange§NMS
quoteType§EQUITY
shortName§Simulations Plus, Inc.
longName§Simulations Plus, Inc.
firstTradeDateEpochUtc§866640600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§fdc1976c-6b80-3a0e-9129-b43bc4d9255c
gmtOffSetMilliseconds§-18000000
targetHighPrice§55.0
targetLowPrice§51.0
targetMeanPrice§53.67
targetMedianPrice§55.0
recommendationMean§1.3
recommendationKey§strong_buy
numberOfAnalystOpinions§3
quickRatio§14.804
earningsGrowth§0.625
grossMargins§0.78086996
ebitdaMargins§0.24334998
trailingPegRatio§None
